Spots Global Cancer Trial Database for NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
Official Title: Phase 1 Study of NT-I7 (rhIL-7-hyFc) for the Treatment of Kaposi Sarcoma in Patients With or Without Infection With HIV
Study ID: NCT04893018
Interventions
Study Description
Brief Summary: This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT-I7 may work better in treating Kaposi sarcoma.
Detailed Description: OUTLINE: This is a dose-escalation study. Patients receive efineptakin alfa intramuscularly (IM) on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up on day 30 (+/- 7 days) and then every 12 weeks for 12 months.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zuckerberg San Francisco General Hospital, San Francisco, California, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Harborview Medical Center, Seattle, Washington, United States
Contact Details
Name: Chia-Ching (Jackie) Wang
Affiliation: University of California, San Francisco
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
